A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Trial Profile

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Epacadostat (Primary) ; INCB 50465 (Primary) ; Itacitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 05 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top